110 results about "Cannabinol" patented technology

The present invention relates to a method for preparing a Cannabis plant Δ9-tetrahydrocannabinol isolate from a crude solvent extract of Cannabis plant material. The invention relates further to a Cannabis plant THC isolate comprising Δ9-tetrahydrocannabinol, Cannabinol (CBN) and/or Cannabidiol (CBD) and to a pharmaceutical composition comprising the Cannabis plant THC isolate.

The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.

The present invention provides a method for extracting cannabidiol, and belongs to the technical field of industrial extraction. The method comprises the following operation steps of drying the flowers and leaves of a mariguana plant, grinding and crushing, performing reverse extracting on the crushed coarse powder and a solvent in a reverse extracting device along the opposite directions, and enabling the solvent to extract the effective components of the coarse powder out of an extracting solution; performing pressure-relief heating on the extracting solution, and volatilizing the excessiveethanol in the extracting solution, so as to obtain a concentrated solution of cannabidiol; adding purified water into the concentrated solution of cannabidiol, diluting, eluting by a chromatography column in a gradient way, and collecting a target eluting solution; combining the target eluting solution, and performing pressure-relief concentrating at the temperature of 50 to 70 DEG C, so as to obtain a secondary concentrated solution of cannabidiol; adding 90%w/w ethanol over-saturated solution into the secondary concentrated solution of cannabidiol, obtaining a crystallized product, washingby the purified water, and drying, so as to obtain a cannabidiol product. The method has the advantages that the method can be applied to large-scale continuous production; the working is continuous without interruption; the output is high; the energy source is saved; the safety and reliability are realized.

The present invention is directed to the novel use of complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of α-CD, β-CD and γ-CD and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrahydrocannabinol and cannabidiol.

A method for preparing a purified cannabis extract may comprise extracting a crude extract from cannabis solids, dewatering the crude extract, removing chlorophyll from the crude extract, and distilling the crude extract thereby creating a purified cannabis extract. The extracting step may include contacting crude cannabis solids with an organic ester, thereby creating the crude extract and waste solids. The dewatering step may include contacting the crude extract with a solid dewatering agent and filtering the crude extract from the solid dewatering agent. The removing chlorophyll step may include contacting the crude extract with a solid absorbent agent, and filtering the crude extract from the solid absorbent agent.

The present invention relates to non-psychoactive derivatives of tetrahydro-cannabinol, which exhibit anti-inflammatory and analgesic activities. In particular, the present invention relates to methods of administering the derivatives and pharmaceutical compositions as therapeutic agents in the treatment of pain and tissue inflammation.

The invention belongs to the technical field of biotechnology, and particularly relates to a preparation method for industrial preparation and production of cannabidiol. The preparation method comprises the following steps: (1), adopting industrial hemp as a raw material and ethanol and water as solvents, and performing extraction and water extraction to obtain filtrate including components of theraw material; (2), performing solvent recovery on the obtained filtrate through a thin-film evaporator so as to obtain extract paste, and performing distillation on the extract paste to obtain cannabidiol-rich matter; and (3), separating and purifying the cannabidiol from the cannabidiol-rich matter by using column chromatography. Through the preparation method, environmental pollution is reduced, the process flow is simplified, the yield is improved, and the investment cost is reduced.

The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (cannabis; THC) employing a carrier conjugate of an intermediate in the biosynthesis of cannabis, more particularly 5-pentylresorcinol conjugated to a macromolecular carrier via its hydroxyl groups. By employing such a conjugate with anti-THC antibody in a lateral flow immunochromatography test device convenient on-site testing for low levels of cannabis in liquid samples may be achieved. Such testing is particularly favoured for roadside testing for cannabis in oral fluid samples.

Terpene-enriched cannabinoid composition. Cannabinoid compositions are described including at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes; less than 5% by weight glycol; and less than 20% by weight water, where said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said composition is about 0.1 to about 1.0. Also described are the above compositions where said non-cannabinoid, non-terpene carrier comprise less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming terpene-enriched cannabinoid compositions with enhanced therapeutic effect compared with that of a composition comprising the same cannabinoids amounts and one half the amount of said primary terpene.

The present invention is directed to novel complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of RM-β-cyclodextrin, DM-β-cyclodextrin and TM-β-cyclodextrin, and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrhydrocannabinol and cannabidiol.

The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma. The combination of THC and CBD appears to be particularly effective in reducing cell viability and cell migration in this disease. Preferably the THC and CBD are used is in the form of a highly purified extract of cannabis such that the cannabinoids are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the THC and CBD may be a synthetically produced cannabinoid.

The invention discloses the use of cannabinoid compounds or pharmaceutically acceptable salts thereof in the preparation of pharmaceutical compositions for the treatment of neurodermatitis, wherein the cannabinoid compounds can be selected from one of tetrahydrocannabinol, cannabinol, hypocannabinol and tetrahydrocannabinol, or the cannabinoid compounds can be selected from the group consisting of(1) a combination of tetrahydrocannabinol and tetrahydrocannabinol; (2) a combination of cannabinol and hypocannabinol; (iii) a combination of tetrahydrocannabinol and hypocannabinol; (4) a combination of cannabinol and tetrahydrocannabinol; (5) a combination of cannabinol, hypocannabinol and tetrahydrocannabinol; (6) a combination of tetrahydrocannabinol, hypocannabinol and tetrahydrocannabinol.

The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.

The invention relates to the technical field of detection, in particular to a qualitative and quantitative detection method of one or more of cannabidiol, cannabidiolic acid and tetrahydrocannabinol.The qualitative and quantitative detection method of one or more of the cannabidiol, the cannabidiolic acid and the tetrahydrocannabinol comprises the following steps that: ultrasound extraction is conducted on smashed hemp flower leaves through methyl alcohol, and a test solution is obtained; the test solution is separated and detected through high performance liquid chromatography, a moving phase of the high performance liquid chromatography is a mixture of acetic acid water solution and acetonitrile, and isocratic elution is conducted; and the content of one or more of the cannabidiol, thecannabidiolic acid and the tetrahydrocannabinol are detected through an external standard method. According to the qualitative and quantitative detection method of one or more of the cannabidiol, thecannabidiolic acid and the tetrahydrocannabinol, specific wave length and a moving phase are selected, the peak pattern is good, sensitivity is high, research is conveniently conducted, and qualitative and quantitative treatment of the cannabidiol, the cannabidiolic acid and the tetrahydrocannabinol can be detected quickly and accurately under treatment of the same sample.

The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.

The invention relates to a preparation method of cannabidiol crystals. The preparation method comprises following steps: 1, industrial hemp flower and leaf powder is subjected to decarboxylation and extraction so as to obtain a decarboxylation extracted product; 2, the decarboxylation extracted product is mixed with a first solvent, an obtained mixture is allowed to stand at a low temperature for precipitation, a precipitate is removed, the obtained solvent containing cannabidiol is subjected to concentration so as to obtain a concentrated extracted product; 3, the concentrated extracted product is mixed with a second solvent, filtering is carried out, an obtained filtrate is subjected to high pressure preparation liquid chromatogram treatment, a fraction containing cannabidiol is collected, and the solvent in the fraction is removed so as to obtain a cannabidiol crude product; and 4, the cannabidiol crude product is mixed with a crystallization solvent, and crystallization is carried out at a low temperature so as to obtain the cannabidiol crystasl. The preparation method is capable of obtaining the high purity cannabidiol crystals at a high total extraction rate, is low in energy consumption and organic solvent consumption amount, is capable of saving more energy, is more friendly to the environment, and is more specifically to be used in industrial applications.